Achondroplasia is a genetic condition that changes how bone grows, and it is the most common cause of disproportionate short stature, sometimes called dwarfism [1].
This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.
Achondroplasia is a genetic condition that affects how bones grow. Most of the long bones in the body start out as cartilage, which is the firm, flexible material you can feel in the tip of your nose. As a child grows, that cartilage is slowly replaced by bone. In achondroplasia this process is slowed down, so some bones end up shorter than usual [1].
The effect is not the same everywhere. The upper arms and thighs are shortened more than the forearms and lower legs, which doctors call rhizomelic shortening. The head is usually larger than average, the forehead is prominent, and the middle of the face sits a little flatter [1].
Achondroplasia is sometimes called a skeletal dysplasia, a general term for conditions that change how the skeleton forms. It is also described as a form of dwarfism. Many conditions cause short stature and they are not all achondroplasia. Hypochondroplasia involves the same gene but is usually milder. Getting the diagnosis right matters, since the health checks and treatments differ [1].
The most widely cited estimate is that achondroplasia occurs in about 1 in 26,000 to 1 in 28,000 live births [1,2]. This is an incidence figure, meaning new cases among babies born. Prevalence is a different measure, meaning the number of people living with a condition at a given time. Reliable global prevalence figures are limited.
Achondroplasia occurs in every population studied, with no strong evidence that it is more common in one ethnic group than another. Some regional studies report different rates, but comparison is difficult. Countries vary in how births are recorded and whether specialist testing is available, and recorded numbers usually count people already diagnosed rather than everyone living with the condition.
Genes are instructions inside our cells. Achondroplasia is caused by a change in a gene called FGFR3, which normally helps control how fast bone grows. The change makes the gene overactive, so it puts too much of a brake on growth [1]. Almost all cases involve one of two specific changes at the same spot in FGFR3, which together account for around 99 percent of cases [1].
Achondroplasia is inherited in an autosomal dominant pattern. That means a single copy of the changed gene is enough to cause the condition, so a person with achondroplasia has a 50 percent chance of passing it to each child if their partner is of average height [1].
Around 80 percent of people with achondroplasia have parents of average height. In these families the genetic change happened newly, around the time of conception [1]. New changes of this kind are more common when the father is older [1]. Nothing a parent did or did not do during pregnancy causes achondroplasia.
If both parents have achondroplasia, each pregnancy carries a 25 percent chance of the baby inheriting the change from both parents. This is called homozygous achondroplasia and it is a severe, life-limiting condition [1]. Families in this situation are usually offered genetic counseling, which is a conversation with a specialist about what the numbers mean for them.
Achondroplasia is usually recognizable at or before birth. Common features include [1]:
Babies often have lower muscle tone and may sit, crawl and walk later than other children, catching up over time. Thinking and learning are typically in the average range unless a complication affecting the brain develops [1].
Some health problems are more likely. Ear infections are frequent and, if untreated, can affect hearing and speech. About 40 percent of people with achondroplasia have hearing loss that affects daily life [1]. Breathing pauses during sleep, called sleep apnea, are common in children and adults [1]. In adults the most common problem is narrowing of the lower spine, called spinal stenosis, which can cause leg pain, numbness or weakness [1].
When to seek urgent help. In babies the opening at the base of the skull can be narrow and press on the top of the spinal cord. Signs needing prompt medical attention include pauses in breathing, unusual floppiness or stiffness, very poor feeding, or sudden loss of skills already learned [1,6]. In adults, new problems with bladder or bowel control alongside leg symptoms should be treated as urgent, since nerve damage at that stage may not be reversible [1].
In most people the diagnosis is made from physical features and X-rays, often soon after birth and sometimes during pregnancy on a routine ultrasound scan [1]. A pediatrician usually leads the first review, often alongside a clinical geneticist, who is a doctor specializing in conditions caused by genetic changes. X-rays show a recognizable pattern, including short, sturdy limb bones and a spine where the gaps between certain bones narrow lower down [1].
Genetic testing is not always needed when the clinical and X-ray picture is clear, though it may be requested where there is doubt or where it helps with access to a specific treatment [1]. Testing looks first for the two common FGFR3 changes [1]. Since around 80 percent of cases are new genetic changes, having no family history does not make achondroplasia less likely [1].
There is no cure for achondroplasia. Care has two parts: watching for and treating complications, and, for children, medicines that support growth.
Monitoring. Regular checks are the foundation of care. Guidance from the American Academy of Pediatrics recommends specific reviews from birth onward, including sleep studies and imaging of the junction between the skull and the spine in infancy [3]. Infants and children are generally seen every six to twelve months, and adults every three to five years [1]. Where the opening at the base of the skull is narrow and causing problems, surgery to relieve the pressure can substantially reduce risk in the first year of life [1,6].
Medicines that support growth. Vosoritide is a daily injection approved in the United States and Europe for children with achondroplasia while their growth plates remain open. In trials it increased growth by around 1.57 cm per year [1,5]. Navepegritide is a once-weekly injection approved by the United States Food and Drug Administration in February 2026 for children aged two years and older [1,4]. In Europe a decision on navepegritide was still awaited at the time of writing [4]. Availability and funding differ between countries, so what is offered locally may not match what is approved elsewhere.
Other approaches. Growth hormone adds only around 3 cm to adult height on average [1]. Limb-lengthening surgery can add height, though complications are frequent and there is real debate about when and whether it should be done [1]. Ear tubes, adenoid or tonsil surgery, treatment for sleep apnea, and spinal surgery for stenosis are used when needed [1].
Most people with achondroplasia lead full, independent lives. Care works best when coordinated by a team familiar with skeletal dysplasia. Weight is worth attention, since extra weight adds to back and joint problems, though standard body mass index charts give misleading results and achondroplasia-specific growth charts should be used [1]. Some activities carry higher risk for the neck and spine, and specialists generally advise avoiding collision sports, trampolines, diving from boards and hanging upside down on playground equipment [1].
At school and work, small adaptations make a large difference: step stools, pedal extenders, adjusted desk heights and accessible bathrooms. Hearing should be checked through the primary school years, since untreated ear problems can slow language development [1]. Pregnancy needs planning, with delivery by cesarean section because of pelvic size and a lung specialist involved early [1].
The emotional side is real too. Living with visible difference and other people’s reactions can be wearing, and rates of anxiety and low mood are higher than in the general population [1]. Peer support organizations are listed below.
Clinical trials are research studies that test whether a treatment or approach works and is safe. Achondroplasia is an active research area, so trials come up reasonably often. Deciding whether to look into one is a personal choice, and it helps to take it in steps.
It is worth being clear on what a study involves:
Every trial has rules about who can take part. These are called eligibility criteria. Some rules describe who can join, and others describe who cannot. For an achondroplasia study, the criteria might include a confirmed diagnosis, a particular age range, whether the growth plates are still open, whether a person is already taking a growth-promoting medicine, or whether they have had recent surgery on the spine or the base of the skull.
trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.
Explore achondroplasia clinical trials through trialport
Medical suitability is only part of the picture. A study can be a good match on paper and still be difficult in practice. Worth thinking through:
trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.
Useful questions to put to a research team:
Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.
Search for clinical trials at app.trialport.com.
Research in achondroplasia has moved quickly. Current work falls into a few areas [1]:
Study status checked: 3 August 2026. Recruitment status changes often, so check app.trialport.com for current information.
Beyond Achondroplasia is an international resource with a directory of patient organizations by country, useful if you are outside the US or UK [9]. In the United States, Little People of America is a long-established membership organization offering peer support, local chapters, medical resource lists and advocacy [7]. In the United Kingdom, the Restricted Growth Association supports people with restricted growth and their families, with practical guidance and a member network [8].
National organizations exist across Europe, Australia, New Zealand, Asia, Africa and South America, though coverage is uneven. The Beyond Achondroplasia directory is the most practical starting point [9]. Where no local group exists, a specialist skeletal dysplasia clinic or a national rare disease organization is usually the next best contact.
The actor Peter Dinklage has achondroplasia and has spoken publicly about living with the condition, including how people react to his height [10].
It is worth a note of caution here. Many well-known people of short stature have conditions other than achondroplasia, and short stature has many different causes. Public assumptions about someone’s diagnosis are often wrong, so this page names only people who have described the condition themselves in public.
Is achondroplasia inherited?
It can be, though most cases are not. Around 80 percent of people with achondroplasia have parents of average height and the genetic change was new in them [1]. A person with achondroplasia has a 50 percent chance of passing it to each child if their partner is of average height [1].
What is the life expectancy?
Life span is often close to average, though one study reported it may be reduced by around ten years, largely through heart-related causes in adulthood [1]. Careful monitoring in infancy substantially reduces the risk from pressure at the base of the skull [1].
Is there a cure?
No. Treatment focuses on supporting growth in childhood and preventing or managing complications throughout life [1].
Can adults take the new medicines?
No. Vosoritide and navepegritide are approved for children while their growth plates are still open [1,4].
Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026